Total Payments
$682,304
2024 Payments
$22.20
Companies
12
Transactions
55
Medicare Patients
4,187
Medicare Billing
$679,210
Payment Breakdown by Category
Research$679,807 (99.6%)
Food & Beverage$1,324 (0.2%)
Travel$1,173 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $679,807 | 14 | 99.6% |
| Food and Beverage | $1,324 | 40 | 0.2% |
| Travel and Lodging | $1,173 | 1 | 0.2% |
Payments by Type
Research
$679,807
14 transactions
General
$2,497
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $626,365 | 5 | $0 (2020) |
| GRT US Holding, Inc. | $50,190 | 3 | $0 (2019) |
| Janssen Research & Development, LLC | $1,659 | 11 | $0 (2018) |
| Eli Lilly and Company | $1,656 | 2 | $0 (2018) |
| Allergan Inc. | $1,596 | 4 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $497.36 | 14 | $0 (2024) |
| Alkermes, Inc. | $215.94 | 9 | $0 (2023) |
| Indivior Inc. | $54.31 | 3 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $22.36 | 1 | $0 (2017) |
| Lundbeck LLC | $19.91 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22.20 | 1 | Janssen Pharmaceuticals, Inc ($22.20) |
| 2023 | $287.40 | 8 | Alkermes, Inc. ($168.61) |
| 2022 | $404.10 | 14 | Janssen Pharmaceuticals, Inc ($343.09) |
| 2021 | $71.14 | 4 | Alkermes, Inc. ($22.47) |
| 2020 | $37,989 | 2 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($37,976) |
| 2019 | $72,705 | 6 | GRT US Holding, Inc. ($50,190) |
| 2018 | $567,588 | 14 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($565,892) |
| 2017 | $3,236 | 6 | Eli Lilly and Company ($1,619) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/11/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Neuroscience | ||||||
| 06/27/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: CNS | ||||||
| 06/06/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: CNS | ||||||
| 05/23/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: CNS | ||||||
| 04/11/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: CNS | ||||||
| 03/09/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $118.79 | General |
| Category: Neuroscience | ||||||
| 03/07/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: CNS | ||||||
| 01/31/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: CNS | ||||||
| 01/18/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: CNS | ||||||
| 12/21/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: Neuroscience | ||||||
| 11/22/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: CNS | ||||||
| 11/22/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Neuroscience | ||||||
| 11/17/2022 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $90.52 | General |
| Category: Neuroscience | ||||||
| 09/20/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Neuroscience | ||||||
| 08/17/2022 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: BH | ||||||
| 08/02/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Neuroscience | ||||||
| 07/08/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: Neuroscience | ||||||
| 06/16/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $121.49 | General |
| Category: Neuroscience | ||||||
| 06/02/2022 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: BH | ||||||
| 05/11/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: Neuroscience | ||||||
| 04/12/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Neuroscience | ||||||
| 03/23/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Neuroscience | ||||||
| 02/01/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Neuroscience | ||||||
| 11/30/2021 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Neuroscience | ||||||
| 08/05/2021 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PROTOCOL 331-201-00080 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $548,808 | 2 |
| KF7013-04 | GRT US Holding, Inc. | $50,190 | 3 |
| A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $39,581 | 2 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $37,976 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $1,656 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | Allergan Inc. | $1,596 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 779 | 1,440 | $672,764 | $125,629 |
| 2022 | 9 | 584 | 1,162 | $148,451 | $78,744 |
| 2021 | 10 | 1,163 | 2,823 | $326,650 | $199,835 |
| 2020 | 13 | 1,661 | 3,658 | $424,670 | $275,002 |
Total Patients
4,187
Total Services
9,083
Medicare Billing
$679,210
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 137 | 410 | $225,950 | $40,860 | 18.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 210 | 464 | $174,650 | $30,392 | 17.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 191 | 201 | $140,315 | $28,809 | 20.5% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Facility | 2023 | 105 | 222 | $55,500 | $11,268 | 20.3% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 42 | 44 | $33,049 | $6,329 | 19.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 47 | 50 | $28,600 | $4,833 | 16.9% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Facility | 2023 | 47 | 49 | $14,700 | $3,139 | 21.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Facility | 2022 | 173 | 479 | $48,200 | $25,213 | 52.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 113 | 253 | $27,100 | $15,199 | 56.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 79 | 81 | $30,750 | $13,394 | 43.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 88 | 156 | $19,975 | $13,217 | 66.2% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Facility | 2022 | 41 | 41 | $5,825 | $2,733 | 46.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 26 | 44 | $4,400 | $2,632 | 59.8% |
| 99334 | Established patient custodial care facility, group care, or assisted living visit, typically 15 minutes | Office | 2022 | 20 | 36 | $2,700 | $1,850 | 68.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 16 | $3,537 | $1,811 | 51.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 16 | 16 | $2,000 | $1,434 | 71.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 14 | 40 | $3,965 | $1,261 | 31.8% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Facility | 2021 | 329 | 1,215 | $120,925 | $65,174 | 53.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 212 | 568 | $71,250 | $49,971 | 70.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 163 | 526 | $51,900 | $32,322 | 62.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 153 | 155 | $38,750 | $26,002 | 67.1% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Facility | 2021 | 125 | 126 | $15,725 | $8,568 | 54.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 91 | 92 | $11,600 | $8,444 | 72.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 18 | 18 | $3,600 | $2,679 | 74.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 23 | $4,600 | $2,453 | 53.3% |
About Dr. Anil Sharma, MD
Dr. Anil Sharma, MD is a Psychiatry healthcare provider based in Inglewood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447328109.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anil Sharma, MD has received a total of $682,304 in payments from pharmaceutical and medical device companies, with $22.20 received in 2024. These payments were reported across 55 transactions from 12 companies. The most common payment nature is "" ($679,807).
As a Medicare-enrolled provider, Sharma has provided services to 4,187 Medicare beneficiaries, totaling 9,083 services with total Medicare billing of $679,210. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Inglewood, CA
- Active Since 12/01/2006
- Last Updated 10/20/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1447328109
Products in Payments
- REXULTI (Drug) $626,365
- Neridronic acid (Drug) $50,190
- INVEGA SUSTENNA (Drug) $406.84
- ARISTADA (Drug) $175.29
- SPRAVATO (Drug) $90.52
- PERSERIS (Drug) $54.31
- ABILIFY MAINTENA (Drug) $42.27
- LYBALVI (Drug) $40.65
- AUSTEDO (Drug) $15.48
- FLEXITOUCH (Device) $13.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.